skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

About Susan

Boston, USA

25+ years of experience

Susan Danheiser
Susan Danheiser is the therapeutic area lead for CNS, autoimmune/inflammation and ophthalmology in Trialtrove. Susan oversees content development and strategy, and provides solutions for our clients’ most challenging business questions.

Susan joined Citeline in 2004, building out clinical trials content and processes in oncology and launching Citeline’s custom analytics and consulting services before transitioning to her current role.

Prior to that, she worked in corporate market analytics at Ipsen and owned her own consulting business, specializing in competitive and market intelligence with companies including Decision Resources and Fuld & Company.

Driving product enhancements to address industry trends and client needs (in biomarkers, companion diagnostics, and real world evidence, to name a few), are among Susan’s most important contributions during her tenure at Citeline.


Analyst Articles

Articles by Susan

  • Trialtrove

    Clinical Trials Activity Analysis: Factoring in Delayed Reporting

    By Susan Danheiser 09 Jul 2018

    Clinical Trials Activity Analysis: Factoring in Delayed Reporting

    The timing of when sponsors report clinical trials in the public domain continues to be a topic of interest.  Despite efforts to regulate and encourage prospective reporting of study starts, delayed reporting remains and is a factor that is often overlooked when evaluating clinical trial trends.  Here, we examine the magnitude of clinical trial reporting delays and how they can be accounted for in your analyses.

    Topic Clinical trials